Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ORGANIZATION
ORGANIZATION
- Wholesale Industry FTC to Discuss Prohibiting Free-of-Charge Inventory Transfers between Pharmacies
May 30, 2017
- JPMA Will Be Watching Discussions on Eligibility Criteria for Companies to Receive Price Maintenance Premium
May 29, 2017
- Suzuki to Serve His 3rd Term as JPWA Chief
May 26, 2017
- Japan Microbiome Consortium Inaugurated by Drug Makers to Promote Drug Discovery Research
May 25, 2017
- Price Band Rule Raising Prices of Rock-Bottom Generics: Sawai President
May 24, 2017
- Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
May 17, 2017
- Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA
May 15, 2017
- JGA’s 1st Industry Vision Envisages Consolidation into 4 Biz Models
May 8, 2017
- JPMA to Draw Up Proposals on Continuous Manufacturing: Quality & Technology Committee
April 27, 2017
- JPMA to Focus on New Developments Including GCP Reform in FY2017: Drug Evaluation Committee
April 27, 2017
- Broader Approach to HTA Could Be Used to Validate Initial Pricing Premiums: PhRMA HTA Chief
April 26, 2017
- JPMA to Focus on Initiative to Reflect Post-Marketing Evidence for Efficacy in Package Inserts
April 26, 2017
- JPMA Says Bayer Rep Contacted It Last July over Xarelto Survey, Issue Should Be First Handled by Regulators
April 24, 2017
- PhRMA Submits Paper to Lawmaker Group, Demands Price Maintenance for On-Patent Drugs
April 21, 2017
- Innovation Premium Top Priority for 3 Trade Groups; EFPIA Ideally Wants Its Expansion
April 20, 2017
- Masaru Nakamura Resigns as Chairman of NPhA in Wake of False Claim Scandal Involving Qol
April 18, 2017
- PhRMA Chair Repeats Call for Keeping Price Maintenance Premium to Secure Market Predictability
April 13, 2017
- JGA Fires Back at Criticism on “Excessive” and “Expensive” Generics, Says No. of Makers Not So Many
April 11, 2017
- Asian Industry Groups Promote Collaboration to Discover Drugs from Natural Resources by Leveraging Asia’s Diverse Ecosystems
April 10, 2017
- JPMA to Support Japanese Drug Makers’ Overseas Expansion through Public-Private Cooperation
April 10, 2017
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…